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Background: There is limited data available regarding safety profile of artemisinins in early pregnancy. They are,
therefore, not recommended by WHO as a first-line treatment for malaria in first trimester due to associated
embryo-foetal toxicity in animal studies. The study assessed birth outcome among pregnant women inadvertently
exposed to artemether-lumefantrine (AL) during first trimester in comparison to those of women exposed to other
anti-malarial drugs or no drug at all during the same period of pregnancy.
Methods: Pregnant women with gestational age <20 weeks were recruited from Maternal Health clinics or from
monthly house visits (demographic surveillance), and followed prospectively until delivery.
Results: 2167 pregnant women were recruited and 1783 (82.3%) completed the study until delivery. 319 (17.9%)
used anti-malarials in first trimester, of whom 172 (53.9%) used (AL), 78 (24.4%) quinine, 66 (20.7%)
sulphadoxine-pyrimethamine (SP) and 11 (3.4%) amodiaquine. Quinine exposure in first trimester was associated
with an increased risk of miscarriage/stillbirth (OR 2.5; 1.3–5.1) and premature birth (OR 2.6; 1.3–5.3) as opposed
to AL with (OR 1.4; 0.8–2.5) for miscarriage/stillbirth and (OR 0.9; 0.5–1.8) for preterm birth. Congenital anomalies
were identified in 4 exposure groups namely AL only (1/164[0.6%]), quinine only (1/70[1.4%]), SP (2/66[3.0%]), and
non-anti-malarial exposure group (19/1464[1.3%]).
Conclusion: Exposure to AL in first trimester was more common than to any other anti-malarial drugs. Quinine
exposure was associated with adverse pregnancy outcomes which was not the case following other anti-malarial
intake. Since AL and quinine were used according to their availability rather than to disease severity, it is likely
that the effect observed was related to the drug and not to the disease itself. Even with this caveat, a change of
policy from quinine to AL for the treatment of uncomplicated malaria during the whole pregnancy period could
be already envisaged.
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Over 60% of all pregnancies globally are at risk of mal-
aria and more than 32 million are in sub-Sahara Africa
[1]. Malaria infection is associated with high maternal
and perinatal mortality in tropical and subtropical re-
gions [2]. Severe maternal anaemia, intrauterine growth
retardation, intrauterine death, stillbirth, premature de-
livery and low birth-weight are some of the reported
substantial direct risks of malaria in pregnancy [2,3]. Al-
though malaria in pregnancy is a serious public health* Correspondence: dfmosha@hotmail.com
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unless otherwise stated.problem, there is limited information available regarding
safety profile of most of licensed anti-malarial in pregnancy
because pregnant women are routinely not involved in
clinical trials related to drug development for fear of harm-
ing the women and or developing foetus [4].
Artemisinin-based combination therapy (ACT) is the
most effective drug combination for Plasmodium falcip-
arum malaria and has been recommended by the World
Health Organization (WHO) as a treatment of choice
for the treatment of P. falciparum malaria [5]. ACT is
only recommended in pregnancy during second and
third trimester, but not in first trimester, unless they
are the only treatment available, or if the patient’s life
is threatened. Safety concerns of artemisinins in firstLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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anomalies following animal studies in early stage of
pregnancy [6,7]. Two previous small-scale studies asses-
sing Zambian and Sudanese pregnant women exposed
to artemisinin during first trimester could not find any
association between drug exposure and maternal or
birth adverse outcomes [8,9]. However, evidence is still
scarce to ensure safety of ACT during first trimester.
Artemether-lumefantrine (AL) (20 mg and 120 mg,
respectively) (Coartem©, Novartis Pharm AG) is one of
the most popular and efficacious fixed dose of ACT
which is currently available [10]. AL was introduced in
Tanzania as a first-line therapy for malaria in 2006 to
replace sulphadoxine-pyrimethamine (SP) [11]. Inadvert-
ent exposure to artemisinin during first trimester of
pregnancy is possible due to its high availability at a sub-
sidized cost in both private and public health facilities in
the country [12,13]. Furthermore, self-treatment of mal-
aria without consulting a trained professional is common
in sub-Sahara Africa; indeed, 70% of malaria episodes in
rural Africa and 50% in urban areas are self-treated cases
[14]. It is, therefore, important to take advantage of the
latter to extend the margin safety information of artemi-
sinin compounds in pregnancy by evaluating maternal
and birth outcomes of inadvertently AL exposure to
women in their first trimester.
There is increasing evidence supporting efficacy, safety
and tolerability of ACT, which outweigh the advantages
of quinine in treating malaria [15,16]. Despite its reacto-
genicity profile and several reports of resistant strains of
P falciparum [17,18], quinine remains the only recom-
mended drug for treating both uncomplicated and com-
plicated P falciparum malaria during first trimester of
pregnancy [5,11]. The present study aims at assessing
the maternal and birth outcomes in pregnant women
who were inadvertently exposed to AL during first tri-
mester in comparison to those of women exposed to
other anti-malarial drugs or no drug at all during the
same period of pregnancy using two Health Demographic
Surveillance System (HDSS) platforms in Tanzania.
Methods
Study area
The study was conducted in Rufiji and Kigoma HDSS in
Tanzania. Rufiji HDSS is in a rural setting while Kigoma
HDSS is in an urban one, both areas have moderate to
high malaria transmission intensity [19]. The study in-
volved a total of 22 health facilities in the two HDSS
sites. There was no clinical interventional research activ-
ity in the area during the study period.
Study design
The study enrolled pregnant women with gestational
age of 20 weeks and below between April 2012 andMarch 2013. Only women residing in HDSS were eligible
for the study. They were recruited from Reproductive
and Child Health (RCH) clinic during their routine visits
and from the community through monthly round-based
house visits. The set-up of HDSS allows identification of
pregnancy status in women of childbearing age through
routine HDSS quarterly census. On the day of enrolment,
participants were interviewed for obstetrics and previous
medical history including history of chronic illness or dis-
ease, use of alcohol and smoking. Important laboratory
test such as maternal haemoglobin level, screening for
HIV and syphilis were performed. Use of any anti-
malarial during first trimester of the presenting preg-
nancy was the key question during interview. Informa-
tion regarding the reported drug used by a participant
was verified by assessing patient’s medical log in the
attended health facility, prescription sheet and maternal
RCH card. Assessment of RCH card and patient’s medical
log were also carried out for participants who reported
no drug intake. In case of discordance between the facil-
ity medical log and what the participant had reported re-
garding the used medicine, participant’s information was
considered the truth after further interview to verify
specifications of the said medicine, whether it was used
or not. Participants who had inadvertently used AL for
malaria treatment in first trimester were compared with
pregnant women who were treated with either quinine
(Qn), sulphadoxine-pyrimethamine (SP), amodiaquine or
women who had not used anti-malarial drug(s) at all dur-
ing the same period of pregnancy. Thus, women were
not randomized but grouped to the study arm according
to their anti-malarial exposure history in first trimester.
Women were followed on monthly basis until delivery
to monitor pregnancy and birth outcomes. The assessed
pregnancy outcome included maternal mortality, spontan-
eous abortion (pregnancy lose ≤ 28 weeks of gestation), ec-
topic gestation, stillbirth and live birth. Birth outcome
included birth weight, maturity status at birth [estimated
from the last normal menstrual period (LNMP), or fundal
height examination, when the LNMP was unknown] and
presence of congenital anomalies. All newborns were
assessed for congenital abnormalities post-delivery by a
study clinician or health facility midwife. Screening for
congenital abnormalities was performed under the guid-
ance of a specific developed checklist. The screening was
limited to identify external abnormalities regardless of the
degree of severity. No examination was performed to de-
termine neurological score for sensory or motor patterns.
Primary endpoint
Primary endpoints of the study were pregnancy and baby
outcomes. Pregnancy outcome included miscarriage,
stillbirth or live birth whereas baby outcome included
birth weight and prematurity status at birth. Stillbirth
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28 weeks of gestation. Low birth weight was defined as a
birth weight below 2,500 grams and premature was de-
fined as birth before 37 weeks of gestational age.
Statistical analysis
STATA® 12.0 (Stata Corporation, College Station, Texas,
USA) was used for data analysis. Numerical variables
were summarized into mean and standard deviation.
Categorical variables were summarized using cross tabu-
lation to estimate different proportion. The effect of
demographic and pregnancy characteristics on primary
endpoint of the study was assessed by bivariate analysis.
Explanatory variables were included in the multivariate
analysis if the variable had p-value < 0.2 in bivariate ana-
lysis. Logistic regression model were used to estimate
the odds ratio (OR) for the associated between binary
pregnancy outcomes (birth outcome, birth weight and
birth maturity status) and medicine exposure. Two sided
Wald test P-values are presented.
Ethics
Ethical approval was granted by the Ifakara Health Insti-
tute (IHI) ethical review board and the National Institute
for Medical Research (NIMR) ethical committee. Written
informed consent was obtained from all participants.
Results
A total of 2,167 pregnant women were enrolled in the
study and 1,783 (82.3%) were followed until delivery
(Figure 1). 19.2% (342) were recruited from the commu-
nity through house visit and 80.8% (1441) from the facil-
ity during their routine RCH clinic visits. 602 (33.8%)Figure 1 Flow chart of participants in the study. AL = Artemether-lume
AQ = Amodiaquine; None = No anti-malarial.women were recruited in first trimester of pregnancy
with mean gestational age of 10.5 [standard deviation
(SD) 2.6] and 1181 (66.2%) during the first half of sec-
ond trimester of pregnancy with mean gestation age of
16.9 (1.5). 559 (31.4%) were primigavidae, 336 (18.8%)
secundigravidae and 888 (49.8%) were multigravidae
with gravidity of 3 and above. Important demographic
and clinical characteristics are summarized in Table 1.
Drug exposure
319 (17.9%) women used anti-malarial in first trimester
of pregnancy because of a morbid episode. 164 (51.4%)
used AL only, 70 (21.9%) quinine only, 8 (2.5%) both AL
and quinine, 66 (20.7%) SP and 11 (3.4%) amodiaquine.
At least 88% of study women used three group of drugs
that are in antenatal intervention as recommended
by the Ministry of Health [11] namely, anthelminthic,
sulphadoxine-pyrimethamine (SP) for intermittent pre-
ventive treatment of malaria (IPTp) and iron and folic
acid supplementation. Anthelminthic and IPTp-SP are
prescribed in second and third trimester of pregnancy.
1579 (88.6%) used anthelminthic (mebendazole), 1626
(91.2%) used iron and folic acid supplementation and
1636 (91.8%) used at least one dose of IPTp-SP.
Pregnancy outcome and anti-malarial exposure
Among 1783 deliveries, there were 5 maternal deaths
that occurred within 24 hours, three were due to post-
partum haemorrhage and the remaining two each was
secondary to eclampsia and disseminated intravascular
coagulopathy (DIC), respectively. Pregnancy outcomes
included 44 (2.5%) abortions, 62 (3.5%) stillbirth and
1677 (94.1%) live births. Baby outcomes included 81 (4.8%)fantrine; Qn = Quinine; SP = Sulphadoxine-pyrimethamine;
Table 1 Characteristics of pregnant women enrolled in the study
Characteristics First trimester First half of second trimester All trimesters
n = 602 n = 1181 n = 1783
Mean age, (years)* 25.7 (6.8; 14 – 49) 25.9 (6.7; 13 – 46) 25.8 (6.8; 13 – 49)
Mean BMI* 23.2 (3.9; 14.2 – 39.6) 23.3 (3.6; 14.0 – 42.5) 23.4 (3.7; 14.0 – 42.5)
Mean gestational age, (weeks)* 10.5 (2.6; 3 – 12) 16.9 (1.5; 13 – 20) 14.8 (3.7; 3 – 20)
Gravidity#
Primigravidae 182 (30.0) 377 (31.9) 559 (31.4)
Secundigravidae 109 (18.0) 227 (19.2) 336 (18.8)
3 – 4 pregnancies 180 (29.6) 315 (26.7) 495 (27.8)
≥ 5 pregnancies 131 (21.4) 262 (22.2) 393 (22.0)
Recruited sites#
Health facility 468 (22.3) 973 (82.4) 1441 (80.8)
Home 134 (77.7) 208 (17.6) 342 (19.2)
Drinking alcohol# 14 (2.7) 27 (2.3) 41 (2.3)
Smoking cigarette# 5 (0.8) 2 (0.2) 7 (0.4)
Haemoglobin level (g/dl)* 10.8 (1.5; 5.0 – 14.6) 10.7 (1.5; 5.4 – 14.9) 10.7 (1.5; 5.0 – 14.9)
HIV status#
Negative 533 (88.5) 1086 (92.0) 1619 (90.8)
Positive 18 (3.0) 46 (3.9) 64 (3.6)
No results 51 (8.5) 49 (4.1) 100 (5.6)
Syphilis test#
Negative 521 (86.5) 1082 (91.6) 1603 (89.9)
Positive 12 (2.0) 15 (1.3) 27 (1.5)
No results 69 (11.5) 84 (7.1) 153 (8.6)
Abbreviation: BMI = Body Mass Index.
*Represents data presented in mean, (standard deviation [SD]; range).
#Represent data presented in number (%).
Table 2 Pregnancy and baby outcomes in relation to anti-malarial exposure status during first trimester
Pregnancy outcome AL only AL & Quinine Quinine only SP Amodiaquine None
164 (%) 8 (%) 70 (%) 66 (%) 11 (%) 1464 (%)
Abortion 5 (3.0) 2 (25.0) 3 (4.3) 0 (0.0) 0 (0.0) 34 (2.3)
Stillbirth 6 (3.7) 0 (0.0) 5 (7.1) 2 (3.0) 0 (0.0) 49 (3.3)
Live birth 153 (93.3) 6 (75.0) 62 (88.6) 64 (97.0) 11 (100) 1381 (94.3)
Birth maturity*
Preterm birth 8 (5.2) 2 (33.3) 8 (12.9) 7 (10.9) 0 (0.0) 88 (6.4)
Full term birth 145 (94.8) 4 (66.7) 54 (87.1) 57 (89.1) 11 (100) 1293 (93.6)
Birth weight*
Low birth weight 8 (5.2) 1 (16.7) 1 (1.6) 2 (3.1) 0 (0.0) 69 (5.0)
Normal birth weight 145 (94.8) 5 (83.3) 61 (98.4) 62 (96.9) 11 (100) 1312 (95.0)
Congenital anomalies 1 (0.6) 0 (0.0) 1 (1.4) 2 (3.0) 0 (0.0) 19 (1.3)
Abbreviation: AL = Artemether-lumefantrine; SP = Sulphadoxine-pyrimethamine.
*Excluded abortion and stillbirth outcomes.
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Table 3 Pregnancy outcomes in relation to anti-malarial exposure status in first trimester
Variables Outcomes Crude OR Pμ Adjusted ORα Pμ
(95% CI) (95%CI)
Birth outcome MC/SB Live birth
n (%) n (%)
AL exposure
Yes 13 (12.3) 159 (9.5) 1.3 (0.7 – 2.4) 0.348 1.4 (0.8 – 2.5) 0.295
No 93 (87.7) 1518 (90.5)
Quinine exposure
Yes 10 (9.4) 68 (4.1) 2.5 (1.2 – 4.9) 0.011 2.5 (1.3 – 5.1) 0.009
No 96 (90.6) 1609 (95.9)
SP exposure
Yes 2 (1.9) 64 (3.8) 0.5 (0.1 – 2.0) 0.318 0.5 (0.1 – 2.0) 0.312
No 104 (98.1) 1613 (96.2)
Amodiaquine exposure
Yes 0 (0.0) 11 (0.7) - (0) - - (0) -
No 106 (100) 1666 (99.3)
No anti-malarial exposure
Yes 83 (78.3) 1380 (82.3) 0.8 (0.5 – 1.3) 0.301 0.8 (0.5 – 1.2) 0.260
No 23 (21.7) 297 (17.7)
Birth weight (grams) < 2500 ≥ 2500
n (%) n (%)
AL exposure
Yes 9 (11.1) 150 (9.4) 1.2 (0.6 – 2.5) 0.608 1.2 (0.6 – 2.5) 0.573
No 72 (88.9) 1446 (90.6)
Quinine exposure
Yes 2 (2.5) 66 (4.1) 0.6 (0.1 – 2.4) 0.463 0.6 (0.1 – 2.4) 0.461
No 79 (97.5) 1530 (95.9)
SP exposure
Yes 2 (2.5) 62 (3.9) 0.6 (0.2 – 2.6) 0.520 0.7 (0.2 – 3.0) 0.639
No 79 (97.5) 1534 (96.1)
Amodiaquine exposure
Yes 0 (0.0) 11 (0.7) - (0) - - (0) -
No 100 (100) 1585 (99.3)
No anti-malarial exposure
Yes 69 (85.2) 1311 (82.1) 1.3 (0.7 – 2.3) 0.485 1.2 (0.6 – 2.3) 0.564
No 12 (14.8) 285 (17.9)
Maturity status at birth Preterm Term
n (%) n (%)
AL exposure
Yes 10 (8.9) 149 (9.5) 0.9 (0.5 – 1.8) 0.812 0.9 (0.5 – 1.8) 0.865
No 103 (91.1) 1415 (90.5)
Quinine exposure
Yes 10 (8.9) 58 (3.7) 2.5 (1.3 – 5.1) 0.010 2.6 (1.3 – 5.3) 0.007
No 103 (91.1) 1506 (96.3)
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Table 3 Pregnancy outcomes in relation to anti-malarial exposure status in first trimester (Continued)
SP exposure
Yes 7 (6.2) 57 (3.6) 1.7 (0.8 – 3.9) 0.177 1.8 (0.8 – 4.1) 0.160
No 106 (93.8) 1507 (96.4)
Amodiaquine exposure
Yes 0 (0.0) 11 (0.7) - (0) - - (0) -
No 113 (100) 1553 (99.3)
No anti-malarial exposure
Yes 88 (77.9) 1292 (82.6) 0.7 (0.5 – 1.2) 0.205 0.7 (0.5 – 1.1) 0.168
No 25 (22.1) 272 (17.4)
Abbreviations: AL = Artemether-lumefantrine; MC =Miscarriage; SB = Stillbirth; SP = Sulphadoxine-pyrimethamine.
RR = Relative Risk; CI = Confidence Interval.
μEstimated from the logistic regression model with Wald type P-value.
αAdjusted for age and parity.
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23 (1.3%) of the newborns were identified to have congeni-
tal anomalies at birth including, polydactyl 17 (73.9%), club
foot 2 (8.7%), genital defect 2 (8.7%), spina bifida 1 (4.3%)
and cardiac defect 1 (4.3%). Congenital anomalies were
identified in four exposed groups namely AL only (1 [0.6%]
of 164), quinine only (1 [1.4%] of 70), SP (2 [3.0%] of 66),
and non-anti-malarial exposed group (19 of [1.3%] of
1464). The median gestational age of anti-malarial expos-
ure in the four exposure groups with congenital anomalies
was 9 (6 – 10) weeks. Table 2 summarizes pregnancy out-
comes parameters in relation to anti-malarial exposure sta-
tus in first trimester.
Quinine exposure during first trimester was associated
with an increased risk of miscarriage/stillbirth (adjusted
OR 2.5; 95%CI 1.3 – 5.1; p = 0.009) and premature birth
(adjusted OR 2.6; 95%CI 1.3 – 5.3; p = 0.007) as opposed
to AL, SP and amodiaquine exposure which were not as-
sociated with increased risk of either miscarriage/still-
birth, low birth weight or premature birth [see details in
Table 3].
Maternal age and parity were assessed to determine
their effect on pregnancy outcome as potential con-
founders of the drug effect. Increase of maternal age in
years was associated with 5% decreased risk of low birth
weight (OR 0.95; p = 0.009), 5% increased risk of miscar-
riage/stillbirth (OR 1.05; p = 0.001), and 3% increased
risk of preterm birth (OR 1.03; p = 0.016). Multigravidae
had 50% decreased risk of low birth weight (OR 0.5;
p = 0.006), 60% increased risk of miscarriage/stillbirth
(OR 1.6; p = 0.048), and 30% increased risk of preterm
birth (OR 1.3; p = 0.099) compared to primigravidae.
Discussion
The study findings provide further evidence on the
safety profile of AL use in early pregnancy to treat mal-
aria. It differs from previous first trimester artemisinins
derivatives safety studies [8,9] by having a larger samplesize and a broader comparative exposure group. Also,
the low mean gestational age at enrolment improves ac-
curacy of drug exposure history, and thus reduces recall
bias. It also increases the chances of identifying adverse
pregnancy outcomes which commonly occurs during
early stage of pregnancy, such as abortion [20].
Although AL is not recommended as first-line treat-
ment for malaria during first trimester of pregnancy, it
was used by 54% of women in this indication. Exposure
to AL in first trimester was twofold higher than quinine,
the drug of choice for malaria treatment during first tri-
mester in Tanzania [11]. This observation suggests that
AL is a popular drug. It reflects its high accessibility in
most of the health facilities and by drug vendors in the
country [12,13]. In practice, quinine was frequently out-
of-stock and its replacement could easily take several
weeks, particularly in public health facilities. The latter
may explain why the efforts of study team to remind cli-
nicians in study health facilities about contraindication
of AL in first trimester had little effect. Since shortage of
drugs is common in resource-limited settings [21,22],
inadvertent or voluntary exposure to contraindicated
drugs is inevitable. Limited access to quinine may also
explain the observed high SP and amodiaquine exposure,
drugs which are currently not recommended for treating
malarial illness [5].
Quinine exposure was associated with a two-fold in-
creased risk of miscarriage, stillbirth and preterm birth.
The harmful effect of quinine during pregnancy has
been known for a long time. Its abortive properties in
relation to the induction of uterine contractions have
long been reported by Maxwell [23]. The strength and
prolongation of these contractions were reported to be
dose dependent. A randomized control trial in Uganda
showed oral quinine to have a two-fold increased inci-
dence of adverse effects compared to AL among preg-
nant women treated for uncomplicated malaria in second
and third trimesters. There were nearly two-fold increases
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the AL one, although the numbers were low. On the other
hand, there was no difference in proportions of spontan-
eous abortions in the two study groups [16].
In the present study, these adverse pregnancy out-
comes were not observed following AL, SP or amodia-
quine exposure, which suggests that the deleterious
effect of quinine was more related to the drug itself, ra-
ther than to the malaria episode. This is supported by
the observation made by fieldworkers that quinine was
not given to a particular group of women because of
more severe disease, but just because AL was more read-
ily accessible on the shelf of the health facility. Also, all
women took quinine tablets, and not intravenous doses,
which suggest a similar degree of severity of the disease
in women who took quinine and AL. However, since it
was not a proper randomized double-blind controlled
trial, it is not possible to formally exclude a selection
bias that would lead to different effects of the malaria
disease itself. Whatever is the cause, the magnitude of
the adverse effects associated with quinine exposure is
alarming, when considering that this drug is viewed at
present as the safest anti-malarial drug in first trimester.
There is a remote possibility of a deleterious effect of AL
on the foetus, and hence on infant development, that
could not be assessed at this stage in the study. We hope
to be able to definitely exclude an adverse consequence
of AL exposure during pregnancy on the infant when
analysing the results of the 12-month follow-up of the
offsprings. Precise information on neurological scores,
including motor and sensory patterns, should assist pol-
icy decisions after careful analysis of the time of anti-
malarial exposure. The preliminary results of the first in-
fant cohort are encouraging.
The observed prevalence of 1.3% congenital anomaly
in the present study is lower than the global prevalence
(3.0%) estimated by WHO [24]. No national figures of
congenital anomalies are available for comparison in
Tanzania. There are obvious limitations to screen for ex-
ternal anomalies only during the neonatal period: This
may lead to an underestimation of the true prevalence of
congenital abnormalities, which may appear later in life.
Congenital anomalies was twice in the non-anti-malarial
exposed group compared to AL exposed group (1.3% vs
0.6%). Polydactyly was the most reported congenital
anomaly (74%), but it is believed to be genetically deter-
mined rather than triggered by external exposure [25].
In animal studies, umbilical hernia has been reported to
be associated with artemisinin exposure during preg-
nancy [6]. The present study had limitation to assess oc-
currence of umbilical hernia since the newborns were
screened only once at the time of delivery. At this time,
hernias may hardly present, and cannot, therefore, be
identified. Also, umbilical hernia is commonly observedin most parts of Africa and is not viewed as an abnor-
mality, it is often not brought to medical attention un-
less it manifests itself with complications such as
intestinal obstruction [26,27].
Conclusion
Exposure to AL in first trimester was more common
than to any other anti-malarial drugs. Quinine exposure
was associated with adverse pregnancy outcome, which
was not the case for other anti-malarials. Since AL and
quinine were used according to their availability rather
than to disease severity, it is likely that the effect ob-
served was related to the drug, and not to the disease it-
self. More information of developmental milestone up to
12 months is needed to rule out any adverse effect on
infancy as a result of AL exposure in first trimester. Even
with this caveat, a change of policy from quinine to AL
for the treatment of uncomplicated malaria during the
whole pregnancy period could be already envisaged.
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